Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.
  • Oral SERD Therapy: Elacestrant's Impact on Metastatic Breast Cancer

    2024-10-10

    IntroductionBreast cancer remains a significant global health challenge, with over 2.3 million new cases diagnosed worldwide in 2022, according to the IARC. The disease burden is disproportionately higher in countries with medium or low levels of the Human Development Index (HDI), where access to in Read More
  • Alopecia Areata: More Than Just Hair Loss

    2024-09-20

    Alopecia areata (AA) is an autoimmune disorder that goes far beyond mere hair loss. While the physical manifestation of patchy or complete hair loss is its most visible symptom, the impact of AA extends deep into the psychological realm, affecting millions worldwide.Understanding Alopecia AreataAlop Read More
  • A $25 Billion Opportunity: Exploring the Enormous Market Impact of Deucravacitinib

    2024-08-01

    Deucravacitinib has emerged as a groundbreaking treatment for moderate-to-severe plaque psoriasis. As we at Unibest keep up with the current pharamceutical blockbusters, we're excited to explore the potential of this novel drug in the enormous oral systemic psoriasis drug market.A Milestone in Deut Read More
  • Market Expansion: Dapagliflozin Receives FDA Approval for Treating Type 2 Diabetes in Children

    2024-06-13

    AstraZeneca has announced on June 12, 2024, that Farxiga (dapagliflozin) has been approved by the U.S. Food and Drug Administration (FDA) for improving glycemic control in children aged 10 years and above with type 2 diabetes (T2D). The FDA approval is based on the positive results from the Phase 3 Read More
  • Avacopan - Orphan Drug with a Growing Market

    2024-06-07

    Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA-associated vasculitis) is a rare but serious autoimmune disease affecting small blood vessels. With a global prevalence estimated between 30-218 cases per million, it leads to inflammation of blood vessels and potential organ damage. C Read More
  • Opportunities for API Manufacturers in the Expanding Ruxolitinib Market

    2024-05-15

    Ruxolitinib, a groundbreaking product of Incyte Corp, has demonstrated an impressive evolution in the pharmaceutical market. Its strategic journey from a niche treatment for rare diseases to a versatile solution for more common dermatological conditions not only emphasizes the strategic significance Read More
  • Seizing the Opportunity in the CGRP Targeting Drugs Market

    2024-02-04

    The global pharmaceutical landscape is witnessing a remarkable surge in the development and approval of drugs targeting trigeminal neuropeptide calcitonin gene-related peptide (CGRP) or its receptor, especially for treating migraine, a debilitating neurological disorder affecting a substantial adult Read More
  • Market Analysis of Vibegron for the Treatment of Overactive Bladder

    2024-01-02

    Prevalence of OABAccording to Statistic Brain, an estimated 183 million people worldwide suffer from overactive bladder (OAB), with North America having the highest prevalence. In the U.S. alone, around 66.6 million people experience OAB symptoms, suggesting a significant market potential for OAB tr Read More
  • Overactive Bladder: An Overview for Global Drug Company BDs And VPs

    2023-12-01

    Overactive Bladder (OAB) is a common urological condition, with significant impacts on patients' quality of life and substantial economic implications for the healthcare market. For stakeholders in the pharmaceutical industry - particularly those targeting the urology market - it's crucial to unders Read More
  • Total 2 pages  Go to Page
  • Go